Cargando…

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary

Detalles Bibliográficos
Autores principales:	Gastaldi, Matteo, Franciotta, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Controversies in Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338691/ https://www.ncbi.nlm.nih.gov/pubmed/37226970 http://dx.doi.org/10.1177/13524585231172960

Ejemplares similares

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Commentary
por: Hohlfeld, R
Publicado: (2021)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018)

Studying the blood–brain barrier will provide new insights into neurodegeneration – Yes
por: Kamphuis, Wouter W, et al.
Publicado: (2018)

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach – NO
por: Hulst, Hanneke E, et al.
Publicado: (2017)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
por: Mühlau, Mark
Publicado: (2022)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes
por: Scalfari, Antonio
Publicado: (2021)

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
por: Cree, Bruce AC
Publicado: (2022)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study
por: Gold, Julian, et al.
Publicado: (2015)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies
por: Hedström, A K, et al.
Publicado: (2016)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sm9bcd1luru95alcj77lo3rdk9